Download - Zombie nation
ZOMBIE-NATIONh y p e r t e n s I v e n a t I o n
By
DR. ABDUL RAB SHAIKHConsultant Interventional Cardiologist
RED CRESCENT INSTITUTE OF CARDIOLOGY
@
RED CRESCENT INSTITUTE OF CARDIOLOGY26TH NOVEMBER , MONDAY , 2012
The LIFE Trial
Losartan Intervention For Endpoint reduction in hypertension study (LIFE)
Presented at the American College of Cardiology
51st Annual Scientific Session
Atlanta, GA
Patients with hypertension (blood pressure 160-200/ 95-115 mm Hg) and left ventricular hypertrophy
AtenololBeta-blocker
Dose titrated to BP <140/90 mm Hg
(n=4,588)
LosartanAngiotensin II antagonist
Dose titrated to BP <140/90 mm Hg
(n=4,605)
Followed for >4 years - Mean follow-up 4.8 years
Cardiovascular death, MI, stroke
LIFE: Study Design
11.0%
12.8%
0%
5%
10%
15%
Losartan Atenolol
P=0.021
Composite of CV Death / MI / StrokeLIFE: Primary Composite Endpoint
Adjusted Hazard Ratio =
0.87
Rate 23.8/1,000 patient yrs
Rate 27.9/1,000 patient yrs
n=508 n=588
4.4%
5.1%
0%
2%
4%
6%
8%
5.0%
6.7%
0%
2%
4%
6%
8%
4.3% 4.1%
0%
2%
4%
6%
8%
P=0.206 P=0.491
Cardiovascular Death Myocardial Infarction
P=0.001
Stroke
LIFE: Individual Endpoint Results
Adjusted HR 0.89
Adjusted HR 1.07
Adjusted HR 0.75
Losartan Atenolol Losartan Atenolol Losartan Atenolol
5.2%
7.0%
0%
2%
4%
6%
8%
10%
Losartan Atenolol
P=0.001
LIFE: New-onset diabetes
Adjusted Hazard Ratio =
0.75
Rate 13.0/1,000 patient yrs
Rate 17.4/1,000 patient yrs
n=241 n=319